NEW YORK, July 23, 2025 /PRNewswire/ — Azure Knowledge Corporation, a global provider of high-quality market research data since 2000, today announced the rebranding of its research arm as Mavrix, marking a strategic evolution in the company’s identity and mission.

Azure Knowledge Corporation Rebrands as Mavrix to Drive AI-Powered Data Intelligence

The rebranding to Mavrix reflects the company’s transformation into a modern data acquisition and intelligence firm. Mavrix specializes in a comprehensive range of data collection methodologies, including Online Panels/Communities, Phone/CATI, Face-to-Face Interviewing, Qualitative Services, Expert Networks, and Custom Recruitment, powered by industry-leading AI-based data quality and visualization tools.

Strategic Evolution for Global Leadership

“This rebrand responds to today’s shifting market landscape,” said Mavrix CEO Rafal Gajdamowicz. “We’re positioning Mavrix as a forward-thinking leader while staying true to our core values: quality, innovation, partnership, and client-focused service.”

The company has a global presence with leadership and operational teams across the U.S., Canada, Europe, and Asia, operating on six continents. They offer 24/7 support, local expertise, and deliver projects in 85+ countries in 40+ languages.

Technology Meets Human Expertise

By combining cutting-edge AI tools with human insight, Mavrix manages complex, multi-country projects using a wide spectrum of methodologies — from online surveys and in-person interviews to immersive environments and qualitative research.

Over 300 organizations worldwide — from Fortune 500s to startups and research firms — trust Mavrix for tailored solutions across finance, tech, healthcare, and consumer goods.

“We focus on building long-term, sustainable partnerships with our clients,” said Neil Blefeld, Managing Director of North America for Mavrix. “Our clients don’t just receive data — they gain insights that drive real advantage.”

Seamless Transition Strategy

The rebrand is being implemented in phases to ensure a smooth and uninterrupted experience for all stakeholders. A new website and refreshed visual identity will spotlight Mavrix’s expanded capabilities and its leadership in data-driven innovation.

Vision for Continued Excellence

Mavrix is committed to delivering transformative impact over the next 25 years in an increasingly complex business environment. Its strategy is designed to lead the industry while upholding the high standards that have defined its legacy. “Our focus is on our clients — 100% — to continue delivering excellence through advanced technologies and research methodologies,” said Glen Collins, EVP – Global Commercial Group.

About Mavrix

Mavrix is a global data and intelligence company offering tech-enabled research solutions. Formerly part of Azure Knowledge, it blends advanced technology with human expertise to deliver quality data and insights worldwide. www.mavrixdata.com

CHENGDU, China, July 23, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or “the Company”, HKEX: 6990) today announced that its partner, Windward Bio AG (“Windward Bio”) has launched its Phase 2 POLARIS clinical study, assessing long-acting dosing of SKB378/WIN378 for people living with asthma.

SKB378/WIN378 is a novel, recombinant fully human monoclonal antibody (mAb) that potently binds to the thymic stromal lymphopoietin (TSLP) ligand and inhibits the TSLP mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor. This is a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological conditions, including asthma and chronic obstructive pulmonary disease (COPD) where inhibition has demonstrated benefit in a wide array of inflammatory phenotypes. SKB378/WIN378 has been engineered to achieve an extended half-life and effector silencing and is subcutaneously administered. SKB378/WIN378 has been studied in a Phase 1 trial which confirmed the half-life for extended dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest tested dose. 

The Phase 2 POLARIS trial is a global, randomized, double-blind, placebo-controlled study evaluating the dosing, safety, and efficacy of SKB378/WIN378 in patients with asthma. Initial data is expected in mid-2026. Additional clinical trials are planned with SKB378/WIN378 including in COPD in 2026. In January 2025, an IND application for SKB378/WIN378 for the treatment of COPD was approved by the National Medical Products Administration (NMPA).

SKB378/WIN378 started as a co-development project jointly conducted by the Company and Harbour BioMed (also known as HBM9378), with both parties equally sharing global rights. In January 2025, it was announced that the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries).

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and other respiratory indications and is also building a pipeline of long-acting bi-specifics targeting validated biology in respiratory and dermatological conditions. Windward Bio launched earlier this year with a $200M Series A led by top-tier investors.

CHENGDU, China, July 23, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or “the Company”, HKEX: 6990) today announced that its partner, Windward Bio AG (“Windward Bio”) has launched its Phase 2 POLARIS clinical study, assessing long-acting dosing of SKB378/WIN378 for people living with asthma.

SKB378/WIN378 is a novel, recombinant fully human monoclonal antibody (mAb) that potently binds to the thymic stromal lymphopoietin (TSLP) ligand and inhibits the TSLP mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor. This is a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological conditions, including asthma and chronic obstructive pulmonary disease (COPD) where inhibition has demonstrated benefit in a wide array of inflammatory phenotypes. SKB378/WIN378 has been engineered to achieve an extended half-life and effector silencing and is subcutaneously administered. SKB378/WIN378 has been studied in a Phase 1 trial which confirmed the half-life for extended dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest tested dose. 

The Phase 2 POLARIS trial is a global, randomized, double-blind, placebo-controlled study evaluating the dosing, safety, and efficacy of SKB378/WIN378 in patients with asthma. Initial data is expected in mid-2026. Additional clinical trials are planned with SKB378/WIN378 including in COPD in 2026. In January 2025, an IND application for SKB378/WIN378 for the treatment of COPD was approved by the National Medical Products Administration (NMPA).

SKB378/WIN378 started as a co-development project jointly conducted by the Company and Harbour BioMed (also known as HBM9378), with both parties equally sharing global rights. In January 2025, it was announced that the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries).

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and other respiratory indications and is also building a pipeline of long-acting bi-specifics targeting validated biology in respiratory and dermatological conditions. Windward Bio launched earlier this year with a $200M Series A led by top-tier investors.

NEW YORK, July 23, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. The NYSE is participating at the All In and Hill and Valley’s “Winning the AI Race” Summit, capturing insights from key voices shaping the future of business, technology, and innovation.  

Ashley Mastronardi delivers the pre-market update on July 23rd

• Stocks are fractionally higher Wednesday morning after President Trump announced a “massive deal” with Japan. This move includes a reciprocal tariff of 15% on exports to the U.S. and Japan investing $550 Billion to the U.S.
• Investors are also paying attention to a slew of earnings throughout the day including NYSE-listed telecommunications giant AT&T. Tesla and Alphabet headline earnings after market close.
• Consumer intelligence company NielsenIQ celebrates its IPO at the NYSE this morning. The company, which raised over $1 billion, will ring the opening bell and begin trading under the ticker symbol NIQ.
• The NYSE is participating in the All In and Hill & Valley “Winning the AI Race” Summit in Washington D.C., engaging with influential leaders and innovators to gather strategic insights on the evolving intersection of AI, business, and technology.  

Opening Bell
NielsenIQ (NYSE: NIQ) celebrates its initial public offering

Closing Bell
Gotham FC celebrates becoming the first American women’s pro soccer club to win a continental competition 

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2736810/NYSE_Market_Update_July_23.mp4 

NEW YORK, July 23, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. The NYSE is participating at the All In and Hill and Valley’s “Winning the AI Race” Summit, capturing insights from key voices shaping the future of business, technology, and innovation.  

Ashley Mastronardi delivers the pre-market update on July 23rd

• Stocks are fractionally higher Wednesday morning after President Trump announced a “massive deal” with Japan. This move includes a reciprocal tariff of 15% on exports to the U.S. and Japan investing $550 Billion to the U.S.
• Investors are also paying attention to a slew of earnings throughout the day including NYSE-listed telecommunications giant AT&T. Tesla and Alphabet headline earnings after market close.
• Consumer intelligence company NielsenIQ celebrates its IPO at the NYSE this morning. The company, which raised over $1 billion, will ring the opening bell and begin trading under the ticker symbol NIQ.
• The NYSE is participating in the All In and Hill & Valley “Winning the AI Race” Summit in Washington D.C., engaging with influential leaders and innovators to gather strategic insights on the evolving intersection of AI, business, and technology.  

Opening Bell
NielsenIQ (NYSE: NIQ) celebrates its initial public offering

Closing Bell
Gotham FC celebrates becoming the first American women’s pro soccer club to win a continental competition 

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2736810/NYSE_Market_Update_July_23.mp4 

STUART, Fla., July 23, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, is proud to announce it will host an exclusive half-day Summit on January 20, 2026, from  11:30 a.m. to 4:30 p.m. (CET) at the prestigious Belvedere Hotel in Davos, Switzerland, alongside the week of the World Economic Forum (WEF) Annual Meeting.

The World Economic Forum, held each January in Davos, is one of the world’s most prestigious gatherings of global leaders from business, government, academia, and civil society. It serves as a unique platform for shaping global, regional, and industry agendas.

Health In Tech’s hosting of a standalone summit at Davos signals its rising influence and its mission to lead global dialogue on equitable, tech-powered healthcare infrastructure.  

This premier event will bring together a curated group of over 75 global decision-makers, including insurance brokers, third-party administrators (TPAs), general agencies, hospital executives, wellness, technology and finance partners.

Attendees will join exclusive conversations and curated panels on next-generation underwriting, the convergence of wearables and data-driven health, value-based plan design, embedded insurance, and transformative financing models that are reshaping global healthcare access.

Health In Tech’s presence not only affirms its credibility on the global stage but accelerates its vision of democratizing care and streamlining insurance delivery through technology. Hosting this independent event in Davos is a strategic opportunity to contribute ideas, forge partnerships, and advancing innovations that can positively impact industries and societies worldwide.

This year’s 2026 summit marks a continuation of Health In Tech’s strong presence at the World Economic Forum, following its active involvement in the 2024 and 2025 Annual Meetings where CEO Tim Johnson and CFO Julia Qian were featured speakers at side events focused on insurance modernization and healthcare innovation.

“Davos is where global ideas gain momentum,” said Tim Johnson, Founder and CEO of Health In Tech. “We’re not just attending, we’re convening. By hosting our own summit, we’re giving our partners, clients, and investors a front-row seat to where the industry is heading. Together, we’ll explore the breakthroughs and partnerships that will shape the future of InsurTech and healthcare delivery.”

Julia Qian, CFO of Health In Tech, echoed the enthusiasm and highlighted the value of creating spaces for collaboration:

“When I spoke on a panel in Davos in 2024, I experienced the incredible energy and insights that come from gathering industry leaders in one place,” said Julian Qian, CFO of Health In Tech. “I’m excited for us now to host our own Summit in 2026 to help drive important conversations that will shape the future of health and insurance technology.”

The Health In Tech Davos Summit aims to foster strategic dialogue and collaboration among industry stakeholders, reinforcing the company’s commitment to being at the forefront of healthcare and insurance innovation.

About Health In Tech 

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

Investor Contact
Investor Relations
ir@healthintech.com

STUART, Fla., July 23, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, is proud to announce it will host an exclusive half-day Summit on January 20, 2026, from  11:30 a.m. to 4:30 p.m. (CET) at the prestigious Belvedere Hotel in Davos, Switzerland, alongside the week of the World Economic Forum (WEF) Annual Meeting.

The World Economic Forum, held each January in Davos, is one of the world’s most prestigious gatherings of global leaders from business, government, academia, and civil society. It serves as a unique platform for shaping global, regional, and industry agendas.

Health In Tech’s hosting of a standalone summit at Davos signals its rising influence and its mission to lead global dialogue on equitable, tech-powered healthcare infrastructure.  

This premier event will bring together a curated group of over 75 global decision-makers, including insurance brokers, third-party administrators (TPAs), general agencies, hospital executives, wellness, technology and finance partners.

Attendees will join exclusive conversations and curated panels on next-generation underwriting, the convergence of wearables and data-driven health, value-based plan design, embedded insurance, and transformative financing models that are reshaping global healthcare access.

Health In Tech’s presence not only affirms its credibility on the global stage but accelerates its vision of democratizing care and streamlining insurance delivery through technology. Hosting this independent event in Davos is a strategic opportunity to contribute ideas, forge partnerships, and advancing innovations that can positively impact industries and societies worldwide.

This year’s 2026 summit marks a continuation of Health In Tech’s strong presence at the World Economic Forum, following its active involvement in the 2024 and 2025 Annual Meetings where CEO Tim Johnson and CFO Julia Qian were featured speakers at side events focused on insurance modernization and healthcare innovation.

“Davos is where global ideas gain momentum,” said Tim Johnson, Founder and CEO of Health In Tech. “We’re not just attending, we’re convening. By hosting our own summit, we’re giving our partners, clients, and investors a front-row seat to where the industry is heading. Together, we’ll explore the breakthroughs and partnerships that will shape the future of InsurTech and healthcare delivery.”

Julia Qian, CFO of Health In Tech, echoed the enthusiasm and highlighted the value of creating spaces for collaboration:

“When I spoke on a panel in Davos in 2024, I experienced the incredible energy and insights that come from gathering industry leaders in one place,” said Julian Qian, CFO of Health In Tech. “I’m excited for us now to host our own Summit in 2026 to help drive important conversations that will shape the future of health and insurance technology.”

The Health In Tech Davos Summit aims to foster strategic dialogue and collaboration among industry stakeholders, reinforcing the company’s commitment to being at the forefront of healthcare and insurance innovation.

About Health In Tech 

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

Investor Contact
Investor Relations
ir@healthintech.com